Radiofrequency-Based Debridement vs. Mechanical Debridement for the Treatment of Articular Cartilage Lesions

September 24, 2021 updated by: Christopher Kaeding

Evaluation of the Efficacy of Radiofrequency-Based Debridement vs. Mechanical Debridement for the Treatment of Articular Cartilage Lesions

The purpose of this study is to evaluate the changes in clinical and imaging outcomes following arthroscopic treatment of chondral lesion(s) by Radiofrequency-Based debridement or Mechanical Debridement in subjects 18-50 years of age.

Study Overview

Detailed Description

This is a non-inferiority, prospective, single blinded, randomized, single-center study design with enrollment of 82 randomized subjects (to assure 70 subjects complete the study). The sample size of 82 participants was calculated from a power analysis. The study was powered to detect at least a seven point change in KOOS pain score based on achieving 80% statistical power to detect a non-inferiority margin. Study duration will be until the last subject enrolled reaches 52 weeks post-operative.

The 82 randomized subjects will be randomized at a 1:1 ratio into the Werewolf Coblation wand treatment group or mechanical debridement treatment group. Subjects will be blinded to their treatment assignment until they complete all study visits. Upon withdraw from the study, termination from the study, or new or recurrent symptoms requiring a subsequent arthroscopy, the blinded assignment will be revealed to the subject.

Study Type

Interventional

Enrollment (Actual)

6

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ohio
      • Columbus, Ohio, United States, 43202
        • The Ohio State University Wexner Medical Center Jameson Crane Sports Medicine Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Given written informed consent on the IRB approved consent form specific to the study, prior to study participation
  • 18-50 years old
  • Male or Female
  • Suspected chondral damage in the following locations where debridement is indicated:

    • Medial femoral condyle
    • Lateral femoral condyle
    • Trochlea
    • Patella
  • < 30% joint space narrowing as seen on x-ray (merchant view, AP and PA Rosenberg)
  • 1 or more chondral lesion(s) as noted on MRI

Exclusion Criteria:

  • Previous chondral treatment in the same compartment (prior debridement and lavage performed more than three months prior to baseline are acceptable)
  • Focal chondral defect indicated for concomitant procedures (i.e., microfracture, ACI, MACI, OATs)
  • Concomitant procedures that are not allowed:

    • Lateral retinacular release
    • Excision of osteophytes
    • Subchondroplasty
    • Manipulation under anesthesia
    • ACL reconstruction
    • Quad tendon repair
    • Patellar tendon repair
    • Patellar tendon debridement
    • Multiligament reconstruction
  • Pregnant and/or intending to become pregnant during this study period

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Radiofrequency-Based Debridement
The Smith and Nephew WEREWOLF COBLATION System is indicated for all soft tissue types in the knee. The WEREWOLF COBLATION System is a FDA cleared bipolar, radiofrequency electrosurgical system designed for use in orthopaedic/arthroscopic surgical procedures.
In this process, radiofrequency energy is used to excite the water molecules in a conductive medium, such as an electrolyte (saline) solution, to generate excited radicals within precisely focused plasma. The energized particles in the plasma have sufficient energy to break molecular bonds (16-18), excising or dissolving (i.e. ablating) soft tissue at relatively low temperatures (typically 40ºC to 70ºC).
Other Names:
  • Werewolf Coblation Wand
Active Comparator: Mechanical Debridement
Arthroscopic chondroplasty used to remove loose and damaged cartilage which minimizes synovial irritation and mechanical impingement

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Knee and Osteoarthritis Outcome Scores (KOOS) activity subscale
Time Frame: change from baseline at week 52 post-op
The previous week is the time period considered when answering the questions. Standardized answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.
change from baseline at week 52 post-op

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual Analogue Scale (VAS)
Time Frame: change from baseline at week 52 post-op
Using a ruler, the score is determined by mea-suring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.
change from baseline at week 52 post-op
International Knee Documentation Committee (IKDC) subjective knee evaluation
Time Frame: change from baseline at week 52 post-op
change from baseline at week 52 post-op
International Knee Documentation Committee (IKDC) objective knee
Time Frame: change from baseline at week 52 post-op
change from baseline at week 52 post-op
Marx Activity Rating Scale (MARS)
Time Frame: change from baseline at week 52 post-op
MARS includes 4 items that assess the frequency of running, cutting, decelerating, and pivoting based on the subjects "healthiest and most active state in the past year." A higher score indicates more functional demand on the knee joint and potentially a higher risk of injury. Each item is scored on a 5-point ordinal scale ranging from 0 (less than 1 time in a month) to 4 (4 or more times in a week), and the total scale score is obtained by summing the individual items' scores (range, 0-16).
change from baseline at week 52 post-op
Work Productivity and Activity Impairment (WPAI V2.0)
Time Frame: change from 1 week post op to 6 weeks post-op
Asks about the effect of patient knee injury on their ability to work and perform normal daily activities
change from 1 week post op to 6 weeks post-op
MRI
Time Frame: change from baseline at week 52 post-op
Baseline MRI will be compared to MRI at 52 weeks to evaluate knee morphology, cartilage signal, osteophytes, bone marrow edema, subarticular cysts, effusions and loose bodies. The international cartilage repair score will be used.
change from baseline at week 52 post-op

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Christopher Kaeding, M.D., Ohio State University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 8, 2018

Primary Completion (Actual)

February 8, 2021

Study Completion (Actual)

February 8, 2021

Study Registration Dates

First Submitted

August 30, 2018

First Submitted That Met QC Criteria

September 18, 2018

First Posted (Actual)

September 20, 2018

Study Record Updates

Last Update Posted (Actual)

September 30, 2021

Last Update Submitted That Met QC Criteria

September 24, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • 2018H0244

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Articular Cartilage Disorder of Knee

Clinical Trials on Radiofrequency-Based Debridement

3
Subscribe